

Intrasense announces CE certification of Liflow® to the new European regulation (MDR)

Montpellier, France, April 29, 2024, at 5:45 pm CEST

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and developer of Myrian® and Liflow®, is proud to announce that the company has obtained CE certification under MDR (European Union Medical Device Regulation 2017/745), for the first version of its Liflow® solution.

On April 22, 2024, the Group received its CE certificate of conformity under MDR for the Liflow® 1.0 solution, a new platform dedicated to oncology imaging. This is the first certified version of Liflow®, marking a significant milestone in Intrasense's product strategy, as it will enable real-life deployment in the first pilot establishments.

Liflow® is a platform for the diagnosis and longitudinal follow-up of cancer patients, providing radiologists with innovative clinical tools enhanced by multi-organ artificial intelligence algorithms, through a unified interface fully integrated into their workflow. Version 1.0 of Liflow® is now available to partner pilot sites, enabling them to evaluate the platform's initial functionalities in a real clinical environment, before commercial deployment in the second half of the year.

R&D teams are currently working on the integration of new artificial intelligence algorithms into version Liflow® 2.0, which will be commercially deployed in the second half of 2024. The ongoing enhancement of this new solution demonstrates Intrasense's commitment to offering ever more innovative solutions to meet the needs of healthcare professionals' daily clinical practice.

About Intrasense

French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced visualization solution for radiology, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow®, a new platform

dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enhance its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

Learn more at www.intrasense.fr

Intrasense

Salomé Sylvestre

Communications officer

Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean

Financial Communication

and investor relations

Phone: +331 44 71 20 40

intrasense@newcap.eu